CAR-T & Cellular Therapy Focus

Explore the latest updates and expert interviews

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Legend Biotech. These supporters have no influence over the production of the content.

Welcome to CAR-T & Cellular Therapy Focus

Explore the latest updates in this field by haematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.

CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.

Latest CAR-T and Cellular Therapy Videos

View all
1:32
Orca-T, a promising platform to treat GvHD
Everett Meyer • 6 Jun 2022
1:45
Matched comparison of tisa-cel and axi-cel in R/R DLBCL
Emmanuel Bachy • 11 Jun 2022
4:08
Utilizing biology to improve on R-CHOP in DLBCL: targeting ubiquitous markers & mutational analysis
Graham Collins • 11 Jun 2022
3:31
PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma
Adam Sperling • 13 Jun 2022

View CAR-T and Cellular Therapy Videos by Disease Area

Multiple Myeloma
Lymphoma
ALL
AML
CLL
3:31
PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma
Adam Sperling • 13 Jun 2022
5:35
Safety & efficacy of ARI0002H in R/R multiple myeloma
Carlos Fernandez de Larrea • 11 Jun 2022
1:11
Toxicities associated with ide-cel in KarMMa
Doris K. Hansen • 4 Jun 2022
0:32
The importance of obtaining real-world data
Doris K. Hansen • 4 Jun 2022
View All Videos
1:45
Matched comparison of tisa-cel and axi-cel in R/R DLBCL
Emmanuel Bachy • 11 Jun 2022
4:08
Utilizing biology to improve on R-CHOP in DLBCL: targeting ubiquitous markers & mutational analysis
Graham Collins • 11 Jun 2022
2:23
ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
Salim Yazji • 10 Jun 2022
0:56
Future directions in T-cell lymphoma
Matko Kalac • 11 Jun 2022
View All Videos
1:32
Orca-T, a promising platform to treat GvHD
Everett Meyer • 6 Jun 2022
3:48
ZUMA-3: impact of prior blinatumomab and alloSCT
Bijal Shah • 4 Jun 2022
1:48
Managing CRS and neurotoxicities associated with CAR-T in ZUMA-3
Bijal Shah • 4 Jun 2022
1:14
Managing ALL patients who relapse after transplantation
Sabina Chiaretti • 12 Jun 2022
View All Videos
3:16
The management of high-risk ALL
Arnon Nagler • 12 Jun 2022
3:24
Replacing autoSCT with immunotherapies: pros and cons
Paul Richardson • 14 May 2022
25:18
Addressing the major challenges to CAR-T therapy in AML
John DiPersio et al. • 30 Apr 2022
0:51
Novel allo-CART therapies and their role in the treatment of hematological malignancies
Roman Galetto • 14 May 2022
View All Videos
1:42
Treating CLL after venetoclax or BTK inhibitors
Mazyar Shadman • 10 Jun 2022
1:52
Cellular therapies and their place in the CLL treatment landscape
Kerry Rogers • 3 Jun 2022
16:12
Exploring the potential of CAR-T therapy in CLL
John Gribben et al. • 30 Apr 2022
2:01
Novel combination therapies for the treatment of CLL
Francesco Forconi • 4 Apr 2022
View All Videos

Features

View all
Approval of axi-cel in second-line for R/R LBCL & label update
Ciltacabtagene autoleucel receives FDA approval for R/R multiple myeloma
Highlights from the EBMT-EHA CAR T-cell 2022 Meeting
Brexucabtagene autoleucel receives FDA approval for R/R B-ALL

View CAR-T and Cellular Therapy Videos by Topic

Nursing
Clinical Practice
Policy
Treatment
Toxicity
Manufacturing
0:52
Nursing and CAR-T therapy
John Murray • 22 Mar 2022
2:29
The nurse’s role in CAR-T therapy
Michelle Kenyon • 14 Feb 2022
2:53
Supporting patients during CAR-T therapy
Michelle Kenyon • 14 Feb 2022
3:09
Educating patients and nurses on CAR-T therapy
Michelle Kenyon • 14 Feb 2022
View All Videos
3:16
The management of high-risk ALL
Arnon Nagler • 12 Jun 2022
2:45
Aims & projects of the GoCART coalition
Christian Chabannon • 11 Jun 2022
1:18
The value of immunotherapies at first relapse
Paul Richardson • 14 May 2022
1:23
Treatment challenges in the age of immunotherapy
Sagar Lonial • 14 May 2022
View All Videos
1:21
Approval of axi-cel in second-line for R/R LBCL & label update
Evandro Bezerra • 23 Apr 2022
2:38
Tackling inequalities in the field of stem cell transplantation and cellular therapies
Nico Gagelmann • 21 Mar 2022
3:35
Engaging with stakeholders to solve CAR-T supply chain and regulatory issues
Christian Chabannon • 22 Mar 2022
4:38
An update on the EBMT Patient Registry & GoCART
Christian Chabannon • 14 Feb 2022
View All Videos
1:32
Orca-T, a promising platform to treat GvHD
Everett Meyer • 6 Jun 2022
1:45
Matched comparison of tisa-cel and axi-cel in R/R DLBCL
Emmanuel Bachy • 11 Jun 2022
4:08
Utilizing biology to improve on R-CHOP in DLBCL: targeting ubiquitous markers & mutational analysis
Graham Collins • 11 Jun 2022
3:31
PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma
Adam Sperling • 13 Jun 2022
View All Videos
1:09
Treatment holidays in multiple myeloma
Graham Jackson • 13 May 2022
1:20
Managing the side effects of CAR-T therapies
Steven Kanner • 10 Apr 2022
2:30
The management of CAR-T related toxicities in leukemia and lymphoma
Marion Subklewe • 21 Mar 2022
2:43
Long-term follow-up results of ZUMA-5: axi-cel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021
View All Videos
3:51
Donor-derived allogeneic CAR-T for B-ALL post-transplant
Claire Roddie • 7 Dec 2019
1:31
The importance of the European Medicines Agency in CAR-T development
Ulrich Jäger
11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al. • 22 Sep 2018
3:08
Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T
John Rossi • 12 Sep 2018
View All Videos

Podcasts

View all
Harnessing the power of immunotherapy in myeloma and amyloidosis
Genomics in the age of immuno-oncology
ASH 2021: a deep dive into ALL immunotherapy
ASH 2021: what did ASH 2021 mean for MDS?

View CAR-T and Cellular Therapy Videos by Therapy Type

CAR T-Cell Therapy
NK-Cell Therapy
1:32
Orca-T, a promising platform to treat GvHD
Everett Meyer • 6 Jun 2022
1:45
Matched comparison of tisa-cel and axi-cel in R/R DLBCL
Emmanuel Bachy • 11 Jun 2022
4:08
Utilizing biology to improve on R-CHOP in DLBCL: targeting ubiquitous markers & mutational analysis
Graham Collins • 11 Jun 2022
2:23
ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
Salim Yazji • 10 Jun 2022
View All Videos
0:40
The current status of CAR T and CAR NK cells in multiple myeloma
Matthew Frigault • 3 Jun 2022
2:45
Challenges faced with the production of universal CAR-T products
Martina Sersch et al. • 14 Apr 2022
1:18
The role of cellular immunotherapies in the future treatment of HL
Yago Nieto • 10 Apr 2022
1:33
The need for novel therapeutic agents in myeloproliferative neoplasms
Naveen Pemmaraju • 11 Apr 2022
View All Videos

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Legend Biotech.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The CAR-T & Cellular Therapy Focus, please contact us.

VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals